AstraZeneca and Merck received approval from the FDA to expand the indication for Lynparza, or olaparib, to cover use as a maintenance therapy in patients with recurrent ovarian cancer that is responsive to platinum-based chemotherapy. The drug was previously approved as a treatment for women with advanced ovarian cancer who had at least three prior treatments with chemotherapy and were no longer responding to it.
AstraZeneca, Merck get expanded approval for Lynparza
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.